Director Nancy Thornberry filed a Form 4 with the SEC on September 4, 2026, reporting two sales of Denali Therapeutics Inc. (NASDAQ:DNLI) common stock executed on September 2, 2026, under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • First sale: Nancy Thornberry disposed of 10,824 shares at a weighted average price of $22.85 per share, with individual sale prices ranging from $22.54 to $23.52.
  • Second sale: An additional 615 shares were sold at a weighted average price of $23.74, with individual prices ranging from $23.59 to $23.85.
  • Remaining ownership: Following both transactions, Thornberry directly beneficially owned 19,686 shares, including 6,408 unvested RSUs.
  • Trading plan: Both sales were made pursuant to a Rule 10b5-1 trading plan adopted June 3, 2026.
  • Role: Thornberry is identified as a Director of Denali Therapeutics Inc.

Nancy Thornberry's Share Sales Under 10b5-1 Plan at Denali Therapeutics

According to the filing, Nancy Thornberry, a Director at Denali Therapeutics Inc., sold a combined total of 11,439 shares of common stock on September 2, 2026. Both transactions were carried out under a Rule 10b5-1 trading plan that Thornberry adopted on June 3, 2026. The form was signed by Tyler Nielsen, acting by power of attorney, and filed on September 4, 2026.

The first transaction involved the disposal of 10,824 shares coded "S" (sale), with a weighted average sale price of $22.85. The filing notes that individual share prices within this transaction ranged from $22.54 to $23.52. Following this sale, Thornberry's direct beneficial ownership stood at 20,301 shares. The second transaction covered 615 shares at a weighted average price of $23.74, with prices ranging from $23.59 to $23.85, bringing the total direct beneficial ownership to 19,686 shares.

The filing discloses that the post-transaction share total of 19,686 includes 6,408 unvested RSUs. Both weighted average prices are described as reportable on a per-share basis upon request by the SEC staff, the issuer, or a security holder of the issuer, according to the filing's footnotes.

What Was Disclosed

The Form 4 reports two open-market sales of Denali Therapeutics common stock by Director Nancy Thornberry on September 2, 2026, totaling 11,439 shares across two transactions, both executed under a pre-adopted Rule 10b5-1 plan. Beneficial ownership following the transactions was 19,686 shares, including 6,408 unvested RSUs.